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World AIDS Day —  
December 1, 2016
World AIDS Day, observed on December 1, draws 
attention to the status of the human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS) 
epidemic worldwide.
The first cases of AIDS in the United States were 
reported more than 35 years ago in the June 5, 1981 
issue of MMWR. Today, approximately 36.7 million 
persons worldwide are living with HIV infection, includ-
ing approximately 2.1 million persons who were newly 
infected during 2015 (1). Although AIDS-related deaths 
have declined by 45% since 2005, an estimated 1.1 million 
persons died from AIDS in 2015 (1), with tuberculosis 
contributing to an estimated 400,000 of these deaths (2).
Global efforts, including the U.S. President’s Emergency 
Plan for AIDS Relief, in which CDC is a key implement-
ing agency, have resulted in 18.2 million persons world-
wide receiving antiretroviral therapy for HIV infection 
by June 2016, an increase from 7.5 million in 2010 (1).
In the United States, an estimated 44,000 persons received 
a diagnosis of HIV infection in 2014 (3). In 2013, an esti-
mated 1.2 million persons in the United States were living 
with HIV, 87% of whom were aware of their infection (4).
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Pediatric human immunodeficiency virus (HIV) infection 
remains an important public health issue in resource-limited 
settings. In 2015, 1.4 million children aged <15 years were 
estimated to be living with HIV (including 170,000 infants 
born in 2015), with the vast majority living in sub-Saharan 
Africa (1). In 2014, 150,000 children died from HIV-related 
causes worldwide (2). Access to timely HIV diagnosis and 
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treatment for HIV-infected infants reduces HIV-associated 
mortality, which is approximately 50% by age 2 years without 
treatment (3). Since 2011, the annual number of HIV-infected 
children has declined by 50%. Despite this gain, in 2014, 
only 42% of HIV-exposed infants received a diagnostic test 
for HIV (2), and in 2015, only 51% of children living with 
HIV received antiretroviral therapy (1). Access to services 
for early infant diagnosis of HIV (which includes access to 
testing for HIV-exposed infants and clinical diagnosis of 
HIV-infected infants) is critical for reducing HIV-associated 
mortality in children aged <15 years. Using data collected from 
seven countries supported by the U.S. President’s Emergency 
Plan for AIDS Relief (PEPFAR), progress in the provision of 
HIV testing services for early infant diagnosis was assessed. 
During 2011–2015, the total number of HIV diagnostic tests 
performed among HIV-exposed infants within 6 weeks after 
birth (tests for early infant diagnosis of HIV), as recommended 
by the World Health Organization (WHO) increased in all 
seven countries (Cote d’Ivoire, the Democratic Republic of the 
Congo, Haiti, Malawi, South Africa, Uganda, and Zambia); 
however, in 2015, the rate of testing for early infant diagnosis 
among HIV-exposed infants was <50% in five countries. HIV 
positivity among those tested declined in all seven countries, 
with three countries (Cote d’Ivoire, the Democratic Republic 
of the Congo, and Uganda) reporting >50% decline. The 
most common challenges for access to testing for early infant 
diagnosis included difficulties in specimen transport, long 
turnaround time between specimen collection and receipt of 
results, and limitations in supply chain management. Further 
reductions in HIV mortality in children can be achieved 
through continued expansion and improvement of services 
for early infant diagnosis in PEPFAR-supported countries, 
including initiatives targeted to reach HIV-exposed infants, 
ensure access to programs for early infant diagnosis of HIV, and 
facilitate prompt linkage to treatment for children diagnosed 
with HIV infection.
WHO currently recommends testing of HIV-exposed infants 
in resource-limited settings using polymerase chain reaction 
(PCR) technology at age 4–6 weeks to optimize detection of 
intrauterine, intrapartum, and early postnatal HIV transmissions 
(4). Data collected during 2011–2015 from one Caribbean and 
(Continued from previous page)
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six sub-Saharan African countries supported by PEPFAR (Haiti 
and Cote d’Ivoire, the Democratic Republic of the Congo, 
Malawi, Uganda, South Africa, and Zambia) were analyzed to 
assess progress in the provision of services for early infant HIV 
diagnosis and adherence to the WHO recommendation.
CDC laboratory advisors from participating countries used 
a standardized questionnaire to abstract laboratory and clinical 
data from national laboratory databases on number of infant 
HIV tests, percent HIV positive, age of infant at time of test, 
turnaround time from specimen collection to return of labora-
tory results to health facility, and mode of specimen transporta-
tion. In addition, information was collected from laboratory 
databases on the number of sites collecting dried blood spots 
(because of simplified collection, transport, and storage, this 
is the type of specimen collected in resource-constrained set-
tings for early diagnosis of HIV among infants); the number 
of laboratories providing services for early infant diagnosis; 
and the number of laboratories enrolled in proficiency testing 
programs. Laboratory managers reported operational chal-
lenges to and successes of testing for early infant diagnosis by 
responding to open-ended questions.
During 2011–2015, the total number of HIV diagnostic 
tests performed for infants increased in all seven countries, 
with the highest increase reported by Uganda (513%) and the 
lowest by Zambia (6%) in 2015 (Table 1). The rate of early 
infant testing performed within 6 weeks of birth among HIV-
exposed infants was low to moderate, varying from 15% in the 
Democratic Republic of the Congo to 62% in South Africa in 
2015. During 2011–2015, an upward trend in testing for early 
infant diagnosis was observed in Cote d’Ivoire and Zambia, 
and a stable trend was observed in Haiti, Malawi, and South 
Africa. Uganda and the Democratic Republic of the Congo 
had a sharp drop in the number of early HIV tests performed 
for infants, with the largest decrease observed from 2014 to 
2015 (Table 1). During 2011–2015, the infant HIV positiv-
ity rate declined in all seven countries, with three countries 
reporting >50% decline. Uganda reported the largest (60%) 
relative decrease, a decline from 10% in 2011 to 4% in 2015; 
Haiti reported the lowest (25%) relative decrease, a decline 
from 8% in 2012 to 6% in 2015.
During 2011–2015, the number of dried-blood-spot col-
lection sites increased in all countries except in South Africa 
and Malawi, where the numbers of sites were stable. In 2015, 
South Africa had the highest number of dried-blood-spot col-
lection sites (n = 3,500); although Haiti had the lowest number 
(n = 129) of collection sites in 2015, the number represented 
a 146% increase in sites compared with 2011. Three countries 
reported more laboratories using PCR to detect HIV infec-
tion among infants: Cote d’Ivoire, the Democratic Republic 
of the Congo, and Malawi. In all seven countries, all labora-
tories performing early infant testing for HIV participated 
in a proficiency-testing program, and all laboratories had a 
proficiency testing score ≥95% during the 5 years.
During 2011–2015, the mean testing turnaround time, 
from blood collection to results returned to the referring 
health facility, was documented in five countries. The short-
est mean turnaround time was 22 days in Haiti in 2012 and 
the longest was 60 days in Uganda in 2012 and 2013. By 
2015, only Cote d’Ivoire and Uganda saw improvements, 
with 50% declines in turnaround time (Table 2). Specimens 
were transported from the referring health facility to the 
testing laboratory by bicycle, motorcycle, or car. Various 
approaches were used for transmitting test results back 
to the referring facility: phone, text messages, email, hard 
copies transported by vehicle, and web-based laboratory–
information-system searches.
The most common reported challenges in access to ser-
vices for early infant diagnosis included weak sample referral 
TABLE 1. Number of infant HIV tests, proportion meeting testing target time frame,* and proportion of HIV-positive tests among HIV-exposed 
infants in testing programs for early infant diagnosis of HIV, by country — one Caribbean and six sub-Saharan African countries, 2011–2015
Country
No. infant HIV tests performed by PCR
% HIV tests performed within  
6 weeks from birth % HIV positive tests
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
Cote d’Ivoire 4,592 5,211 5,693 6,763 7,207 10 29 30 33 39 11 10 9 6 6
Democratic 
Republic of 
the Congo
1,482 2,465 2,441 4,017 2,934 ND 14 25 24 15 11 8 9 6 6
Haiti 2,832 3028 3438 3760 3529 22 28 31 35 34 6 8 7 6 6
Malawi ND 28,816 32,688 35,254 34,152 ND 42 46 47 47 ND 11 7 7 5
South Africa 296,866 329,319 351,694 371,122 482,799 57 59 59 62 62 5 4 4 3 3
Uganda 17,441 77,919 60,984 72,604 106,853 32 31 50 64 37 10 10 8 7 4
Zambia 45,160 48,188 44,877 59,417 47,983 ND ND 30 47 62 8 7 6 6 2
Abbreviations: HIV = human immunodeficiency virus; ND = no data available; PCR = polymerase chain reaction.
* The World Health Organization recommends testing HIV-exposed infants in resource-limited settings using PCR technology at age 4–6 weeks to optimize detection 
of intrauterine, intrapartum, and early postnatal transmissions. 
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networks, long turnaround time, and limitations in supply 
chain management (Table 3). Three countries reported that 
integration of services for early infant diagnosis with other 
programs, including those providing immunizations, pediatric 
care, and health outreach in the community, were integral to 
success of access to testing for early infant diagnosis. Use of 
dried blood spots (Malawi and South Africa) and improve-
ment in specimen referral networks (Malawi and Uganda) also 
were important factors for increasing access to early testing. 
Challenges to implementation of testing for early infant diag-
nosis included mother and child being lost to follow-up, weak 
linkage between programs, (i.e., programs for the prevention of 
mother-to-child transmission and care/antiretroviral therapy), 
and inability to reach infants outside of the health care system.
Discussion
During 2011–2015, among the seven countries assessed, 
the number of infants being tested for HIV infection within 
TABLE 3. Challenges and successes* to access to HIV testing for early infant diagnosis, by country — one Caribbean and six sub-Saharan African 
countries, 2011–2015
Challenge/Success Cote d’Ivoire
Democratic 
Republic of 
the Congo Haiti Malawi
South 
Africa Uganda Zambia
Challenge
Lack of resources for equipment maintenance † C † † † † †
Lack of early infant diagnosis services † † † † C † †
Changes in testing guidelines † † † † C † †
Inconsistencies in data to identify HIV-exposed infant † † † † C † †
Inadequate laboratory data management systems † † † † † C †
Lack of community knowledge on when testing is required † C † † C † †
Weak sample referral networks C C C † † † †
Gaps in supply chain management † C C C † † †
Long turnaround time † C † † C C C
Success
Involvement of community counselors S † † † † † †
Continuous training of service providers S † † † † † †
Standardization of equipment † S † † † † †
Strong collaboration between testing laboratories † S † † † † †
Improved supply chain management † † † S † † †
Improved advocacy campaigns to educate mothers † † † S † † †
Use of additional data to identify HIV-exposed infant † † † † S † †
Parallel scale-up of viral load testing using dried-blood-spot to early  
infant diagnosis testing
† † † † S † †
Improvements in centralized data management † † † † † S †
Use of dried-blood-spot † S † † S † †
Use of sample referral networks † † † S † S †
Integration of early infant diagnosis services with other programs, including 
immunization, pediatric care, outpatient, and outreach
S † S † † † S
Abbreviations: C = challenge; HIV = human immunodeficiency virus; S = success.
* Challenges and successes were based on country self-report.
† Country did not report a particular challenge or success.
TABLE 2. Selected site-level* indicators for testing programs for early infant diagnosis of HIV, by country — one Caribbean and six sub-Saharan 
African countries, 2011–2015
Country
No. health facilities collecting dried-blood-
spot for early infant diagnosis testing
No. laboratories with early  
infant diagnosis testing services
Mean collection-to-results  
turnaround time† (days)
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
Cote d’Ivoire 320 411 420 567 585 3 3 3 4 6 † 45 45 45 22
Democratic Republic 
of the Congo
252 396 549 626 626 3 3 3 3 4 27 27 27 27 27
Haiti 62 74 90 120 129 2 2 2 2 2 23 22 26 37 34
Malawi ND 729 729 729 729 2 3 3 8 8 ND ND ND ND ND
South Africa 3,500 3,500 3,500 3,500 3,500 9 9 9 9 9 ND ND ND ND ND
Uganda 904 1,504 1,684 2,284 1,859 1 1 1 1 1 ND 60 60 30 30
Zambia 106 76 807 1,090 1,077 3 4 4 4 4 35 38 40 38 38
Abbreviations: HIV = human immunodeficiency virus; ND = no data available.
* Site refers to health facility or testing laboratory.
† Mean turnaround time from blood collection at health facility to laboratory results returned to referring facility.  
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6 weeks of birth increased, and HIV positivity among tested 
infants declined (by more than half in three countries). These 
findings demonstrate substantive expansion of programs for 
early infant HIV diagnosis and improvements in the ability 
to monitor trends in HIV positivity among infants. However, 
despite these gains, the percentage of HIV diagnostic tests 
performed on HIV-exposed infants within 6 weeks of birth 
remained below 50% in five of the seven countries. This 
finding is consistent with reports by the Joint United Nations 
Programme on HIV/AIDS that, despite substantial initiatives 
to build capacity for programs for early infant diagnosis of 
HIV, only 42% of HIV-exposed infants received a test for HIV 
within the first 2 months of life in 2014 (3). Initiatives focused 
on improvement of supply chain management, sample referral 
networks (the links between dried-blood-spot collection sites 
and laboratories), and blood collection-to-results turnaround 
time are needed to improve coverage of testing for early infant 
diagnosis for these seven countries to reach the global goal of 
elimination of mother-to-child HIV transmission.
Given the challenges reported with long turnaround times 
from specimen collection to receipt of test results, under-
standing the factors associated with delays in the pretest, test, 
and posttest phase could inform interventions to minimize 
turnaround time and improve follow-up and linkage to 
care. Strengthening specimen referral networks and supply 
chain management needs to take place in half of the coun-
tries assessed, similar to the improvements that have already 
occurred with other laboratory services in resource-limited 
settings (5). Moreover, addressing the issues of integration 
between programs, mothers and children lost to follow-up, 
and the inability to reach children out of the health care sys-
tem is needed to increase access to testing services for early 
infant diagnosis (6).
Despite these challenges, important successes in the PEPFAR 
programs for early infant diagnosis have been recorded. 
PEPFAR has provided testing for early infant diagnosis in sub-
Saharan Africa and the Caribbean, and has improved quality 
of testing through the use of proficiency testing programs 
(7,8). The program for early infant diagnosis has specifically 
helped improve country-level testing quality through the uni-
versal participation and successful performance of countries 
in external quality assurance programs (7). The program for 
early infant testing also has helped pave the way for expanded 
PCR-based technology, such as HIV viral load testing, which 
is the recommended approach for monitoring the effectiveness 
of HIV treatment (9).
The findings in this report are subject to at least three limi-
tations. First, because of the low number of early infant diag-
nostic tests conducted in Haiti and the Democratic Republic 
of the Congo, the changes in HIV positivity observed over 
time may not be valid. Second, data were missing from several 
countries for some periods, making it difficult to assess trends. 
Finally, some data elements were self-reported and dependent 
upon perceptions of the respondent, such as programmatic 
data about successes and challenges of the early infant diag-
nosis program. Despite these limitations, by presenting the 
challenges experienced by these countries, this report provides 
insight into gaps in early infant HIV testing programs, which 
can be used to strengthen and enhance the programs in these 
seven countries.
To date, the global goal of elimination of mother-to-child 
HIV transmission has only been achieved by four countries 
(Armenia, Belarus, Cuba, and Thailand) (10). Meeting the 
call for an AIDS-free generation and reaching the Joint United 
Nations Programme on HIV/AIDS fast-track treatment targets 
for children and infants cannot be achieved without accurate 
and early diagnosis of HIV-infected infants, prompt initia-
tion of lifesaving antiretroviral therapy for these children, and 
lifelong clinical follow-up to ensure sustained viral suppression 
and better health outcomes.
Summary
What is already known about this topic?
Since 2011, the annual number of children infected with human 
immunodeficiency virus (HIV) has declined by 50% worldwide. 
However, in 2014, only 42% of HIV-exposed infants received a 
test for HIV; in 2015, only 51% of children living with HIV 
received antiretroviral therapy. The World Health Organization 
currently recommends testing HIV-exposed infants in resource-
limited settings at age 4–6 weeks.
What is added by this report?
During 2011–2015, in one Caribbean and six sub-Saharan 
countries supported by the President’s Emergency Plan for AIDS 
Relief, the number of tests for early infant diagnosis increased, 
and the HIV-positivity rate declined in all seven countries. 
However, the rate of HIV testing performed within 6 weeks of 
birth among HIV-exposed infants, as recommended by the 
World Health Organization, was <50% in five countries in 2015. 
Difficulties in specimen transport, long turnaround time and 
limitations in supply chain management were among the most 
commonly reported challenges to accessing services for early 
infant diagnosis.
What are the implications for public health practice?
To meet fast-track HIV treatment targets for children and 
infants, accurate and early diagnosis of HIV-infected infants, 
prompt initiation of lifesaving antiretroviral therapy, and 
lifelong clinical follow-up to ensure sustained viral suppression 
are essential.
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